MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy
Clinical trial NCT02089230 · TERMINATED
Trial details
- NCT number
- NCT02089230
- Sponsor
- M.D. Anderson Cancer Center
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-08-27
- Primary completion
- 2019-06-05
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.